ClinicalTrials.gg
Active, not recruitingNCT05600777CALM-2Updated Jul 14, 2026

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Phase 3 interventional study of BLU-5937 and Placebo in Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company. Active, not recruiting at 242 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Primary conditionChronic CoughRegistry: CoughReclassifiedWhy we changed it
Registry
Cough — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Cough
Why
  1. The study's listed conditions name Chronic Cough, a narrower term within Cough.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
997
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.

Enrollment
2nd of 37
997 · median 50
Started
2022
with 4 others
Phase 3
7 of 44
none open now
Primary completion
2026-06
later than 2 of 10 live
Registered
33rd of 44
by date
Lead sponsor
4 of 44
Bellus Health Inc. - a GSK company

Among the 44 studies in Chronic Cough with a site in United States, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2022, is one of 7 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 33rd registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Read the detailed description

The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.

03

Conditions studied

  • Cough
  • Refractory Chronic Cough

Keywords

  • Respiration Disorders
  • Respiratory Tract Diseases
  • Signs and Symptoms, Respiratory
  • Cough
  • Chronic Cough
04

In context

Chronic Cough Reclassified

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

This study's enrollment of 997 is above the median of 60 across 104 interventional studies indexed under Chronic Cough.

Browse Chronic Cough studies →

Lead sponsor

Bellus Health Inc. - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.

First submitted before Bellus Health Inc. became part of GlaxoSmithKline.

Compared within Chronic Cough, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cough. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • chronic cough (including unexplained chronic cough) for at least one year
  • Women of must use a highly effective method during the study and for at least 14 days after the last dose

Exclusion criteria

Exclusion Criteria:

  • Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
  • Diagnosis of , bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
  • Respiratory tract infection within 4 weeks before screening
  • Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
  • History of in the last 5 years
  • History of alcohol or drug abuse within the last 3 years
  • Has a positive serologic test for (HIV), virus surface antigen, or virus.
  • Previous participation in a BLU-5937 trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
997 participants (actual)

Study arms

  • Experimental
    BLU-5937 25 mg

    BLU-5937 oral dose 25 mg twice a day.

    Drug: BLU-5937

  • Experimental
    BLU-5937 50 mg

    BLU-5937 oral dose 50 mg twice a day.

    Drug: BLU-5937

  • Placebo comparator
    Placebo

    Matching Placebo for BLU-5937 oral dose twice a day.

    Drug: Placebo

Interventions

  • Oral administration of BLU-5937 Tablets

    Also known as: Camlipixant

  • DrugPlacebo

    Oral administration of matching placebo for BLU-5937 Tablets

07

What researchers measure

Primary outcomes

  1. 24-Hour Cough Frequency

    Assessed using an ambulatory cough monitor

    Time frame: Week 24

  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

    Time frame: Up to Week 24

  3. Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24

    An AEMI is an event of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring is appropriate. The following are AEMIs for this study: taste disturbance, oral hypoesthesia, oral paresthesia, and new or worsening findings of the cornea.

    Time frame: Up to Week 24

  4. Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

    Time frame: Up to Week 24

  5. Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

    Time frame: Up to Week 24

  6. Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 24

    Time frame: Baseline, Week 24

  7. Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 24

    Time frame: Baseline, Week 24

  8. Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 24

    Time frame: Baseline, Week 24

  9. Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 24

    Time frame: Baseline, Week 24

  10. Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 24

    Time frame: Baseline, Week 24

  11. Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 24

    Time frame: Baseline, Week 24

  12. Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 24

    Time frame: Baseline, Week 24

  13. Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 24

    Time frame: Baseline, Week 24

  14. Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 24

    Time frame: Baseline, Week 24

  15. Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 24

    Time frame: Baseline, Week 24

  16. Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 24

    Time frame: Baseline, Week 24

  17. Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 24

    Time frame: Baseline, Week 24

  18. Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 24

    Time frame: Baseline, Week 24

  19. Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 24

    Time frame: Baseline, Week 24

  20. Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 24

    Time frame: Baseline, Week 24

  21. Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 24

    Time frame: Baseline, Week 24

  22. Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 24

    Time frame: Baseline, Week 24

  23. Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 24

    Time frame: Baseline, Week 24

  24. Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 24

    Time frame: Baseline, Week 24

  25. Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 24

    Time frame: Baseline, Week 24

  26. Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 24

    Time frame: Baseline, Week 24

  27. Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 24

    Time frame: Baseline, Week 24

  28. Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 24

    Time frame: Baseline, Week 24

  29. Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 24

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change from Baseline in Cough Severity Visual Analogue Scale at Week 24

    Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity.

    Time frame: Baseline, Week 24

  2. Percentage of Participants With Greater than or Equal to (>=) 30 mm Reduction From Baseline in Cough Severity Visual Analog Scale at Week 24

    Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity.

    Time frame: Baseline, Week 24

  3. Awake Cough Frequency at Week 24

    Assessed using an ambulatory cough monitor

    Time frame: Week 24

  4. Percentage of Participants With >= 30 percent (%) Reduction From Baseline in 24-Hour Cough Frequency at Week 24

    Assessed using an ambulatory cough monitor

    Time frame: Baseline, Week 24

  5. Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 24

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

    Time frame: Baseline, Week 24

  6. Percentage of Participants With a >= 1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 24

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

    Time frame: Baseline, Week 24

  7. Change from Baseline in the Chronic Cough Diary (CCD) Score at Week 24

    The CCD is a participant-completed daily diary used to assess chronic cough. The CCD score ranges from 0 to 16, with a higher score indicating worse symptoms.

    Time frame: Baseline, Week 24

  8. Percentage of Participants with CCD Response at Week 24

    Percentage of participants with CCD response will be summarized.

    Time frame: Week 24

08

Study locations

242 sites
  • GSK Investigational Site
    Foley, Alabama 36535, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Paramount, California 90723, United States
  • GSK Investigational Site
    Sacramento, California 95661, United States
  • GSK Investigational Site
    San Diego, California 92108, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    San Jose, California 95117, United States
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 96001, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007, United States
  • GSK Investigational Site
    Daytona Beach, Florida 32117, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33324, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Leesburg, Florida 34748, United States
  • GSK Investigational Site
    Orlando, Florida 32713, United States
  • GSK Investigational Site
    Santa Rosa Beach, Florida 32459, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    Sweetwater, Florida 33172, United States
  • GSK Investigational Site
    Cumming, Georgia 30041, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    River Forest, Illinois 60305, United States
  • GSK Investigational Site
    West Des Moines, Iowa 50266, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Chevy Chase, Maryland 20815, United States
  • GSK Investigational Site
    Methuen, Massachusetts 01844, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Edina, Minnesota 55435, United States
  • GSK Investigational Site
    Woodbury, Minnesota 55125, United States
  • GSK Investigational Site
    St Louis, Missouri 55905, United States
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
  • GSK Investigational Site
    Missoula, Montana 59808, United States
  • GSK Investigational Site
    Omaha, Nebraska 68124, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28211, United States
  • GSK Investigational Site
    Gastonia, North Carolina 28054, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Columbus, Ohio 43235, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74136, United States
  • GSK Investigational Site
    Portland, Oregon 97213, United States
  • GSK Investigational Site
    Danville, Pennsylvania 17822, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886, United States
  • GSK Investigational Site
    Anderson, South Carolina 29621, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Charleston, South Carolina 29412, United States
  • GSK Investigational Site
    Franklin, Tennessee 37067, United States
  • GSK Investigational Site
    Dallas, Texas 75231-4307, United States
  • GSK Investigational Site
    Round Rock, Texas 78681, United States
  • GSK Investigational Site
    San Antonio, Texas 78207, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    Macquarie University, New South Wales 2109, Australia
  • GSK Investigational Site
    New Lambton Heights, New South Wales 2305, Australia
  • GSK Investigational Site
    St Leonards, New South Wales 2065, Australia
  • GSK Investigational Site
    Chermside, Queensland 4032, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    St Albans, Victoria 3021, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Spearwood, Western Australia 6163, Australia
  • GSK Investigational Site
    Calgary, Alberta T2N 1N4, Canada
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8L 5G4, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
  • GSK Investigational Site
    Windsor, Ontario N8X 1T3, Canada
  • GSK Investigational Site
    Montreal, Quebec H1Y3H5, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4T3, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4W2, Canada
  • GSK Investigational Site
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Victoriaville, Quebec G6P 3Z8, Canada
  • GSK Investigational Site
    Burlington, ON L7N 3V2, Canada
  • GSK Investigational Site
    Kunshan, Jiangsu, China
  • GSK Investigational Site
    Leshan, Sichuan 614003, China
  • GSK Investigational Site
    Ürümqi, Xinjiang 830001, China
  • GSK Investigational Site
    Beijing, 100730, China
  • GSK Investigational Site
    Changsha, 410008, China
  • GSK Investigational Site
    Chengdu, 610021, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Chongqing, 408099, China
  • GSK Investigational Site
    Dongguan, 523326, China
  • GSK Investigational Site
    Ganzhou, 341000, China
  • GSK Investigational Site
    Guangzhou, 510000, China
  • GSK Investigational Site
    Guangzhou, 510260, China
  • GSK Investigational Site
    Guilin, 541002, China
  • GSK Investigational Site
    Hangzhou, 310003, China
  • GSK Investigational Site
    Hefei, 230001, China
  • GSK Investigational Site
    Hefei, 230022, China
  • GSK Investigational Site
    Hohhot, 010017, China
  • GSK Investigational Site
    Huizhou, 516000, China
  • GSK Investigational Site
    Huizhou, 516001, China
  • GSK Investigational Site
    Jiangsu, 221004, China
  • GSK Investigational Site
    Jinan, 250021, China

Showing the first 100 of 242 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jun 2026, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 31, 2022
StartActual
Dec 5, 2022
Primary completionActual
Jun 10, 2026
CompletionEst.
Mar 17, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05600777
Responsible party
Sponsor
First posted
Oct 31, 2022
Start date
Dec 5, 2022
Primary completion
Jun 10, 2026
Completion
Mar 17, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion